Warning: count(): Parameter must be an array or an object that implements Countable in /home/customer/www/drugtrialsformoney.com/public_html/wp-content/plugins/redux-framework/redux-core/inc/classes/class-redux-output.php on line 373
Study of TTI-622 in Combination With PLD in Patients With Platinum-Resistant Ovarian Cancer - Drug Trials For Money - Paid Clinical Trials

Study of TTI-622 in Combination With PLD in Patients With Platinum-Resistant Ovarian Cancer

Study of TTI-622 in Combination With PLD in Patients With Platinum-Resistant Ovarian Cancer
Conditions:   Ovarian Cancer;   Ovarian Neoplasms;   Ovarian Carcinoma;   Fallopian Tube Cancer;   Epithelial Ovarian Cancer;   Primary Peritoneal Carcinoma
Interventions:   Drug: TTI-622;   Drug: Pegylated Liposomal Doxorubicin
Sponsor:   Trillium Therapeutics Inc.
**RECRUITING NOW**

Source: View full study details on ClinicalTrials.gov

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. By listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.

March 16, 2022 / by / in
Comments